Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $45.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective lifted by Citigroup from $37.00 to $45.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

SNDX has been the topic of a number of other reports. JPMorgan Chase & Co. decreased their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. The Goldman Sachs Group boosted their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, November 7th. StockNews.com raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright upped their price objective on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the stock a “buy” rating in a report on Monday. Finally, UBS Group initiated coverage on Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a “buy” rating and a $37.00 target price on the stock. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $37.64.

Syndax Pharmaceuticals Trading Down 2.2 %

Shares of SNDX stock opened at $15.60 on Tuesday. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of -4.30 and a beta of 0.92. The firm has a 50-day moving average price of $18.71 and a 200 day moving average price of $20.08. Syndax Pharmaceuticals has a twelve month low of $15.00 and a twelve month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.16 million. During the same quarter last year, the business posted ($0.73) EPS. As a group, research analysts predict that Syndax Pharmaceuticals will post -3.69 earnings per share for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. purchased a new position in Syndax Pharmaceuticals in the 2nd quarter valued at about $27,000. Values First Advisors Inc. purchased a new position in Syndax Pharmaceuticals in the third quarter valued at about $30,000. nVerses Capital LLC purchased a new position in Syndax Pharmaceuticals in the second quarter valued at about $33,000. Quantbot Technologies LP acquired a new stake in Syndax Pharmaceuticals during the 3rd quarter valued at approximately $49,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after purchasing an additional 541 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).